StockIQpro
NASDAQ:IPSC

Century Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Century Therapeutics, Inc.'s revenue grew 1556.8% in fiscal 2025 to $109.2M while operating margin rose to −15.8%, its highest in 4 years. Free cash flow was −$104.7M, −95.9% of revenue, and the diluted share count rose 10.1%.Summary generated from Century Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$109.2M
Revenue growth+1556.8%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−15.8%
Net margin−8.8%
ROICn/a
Return on equity−6.0%
Debt / equityn/a
Free cash flow−$104.7M
FCF margin−95.9%
Share count change+10.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a527109
Operating income−95−134−147−138−17
Net income−96−131−137−127−10
Free cash flow−134−17−102−110−105

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)